Implant coating |
Silver nanoparticles/PLGA coating |
Ag+
|
|
[279] |
Bioactive glass nanoparticles/PCL coating |
Cu2+
|
|
[280] |
Ti nanocolumn coating |
Ti nanocolumn |
|
[281] |
TiO2 nanorod coating |
Polydopamine, TiO2, MoS2, RGD |
|
[282] |
Chitosan coating |
hyaluronic acid, gentamicin, deferoxamine |
-
•
drug release was associated with degradation of multilayers triggered by exogenous hyaluronidase
-
•
display effective antifouling and antibacterial properties against E. coli and S. aureus
-
•
enhance the adhesion, proliferation and osteo/angio-genic differentiation of MSCs
|
[283] |
Polymeric coating |
Vancomycin, niosomes |
-
•
prolong drug release up to two weeks
-
•
exhibit no cytotoxic effects towards normal cells
-
•
control bacterial colonization and biofilms formation
|
[284] |
Platforms for bone infection |
Chitosan scaffolds |
Vancomycin, ZIF8 nanocrystals |
-
•
vancomycin encapsulation efficiency for ZIF8 nanocrystals was 99.3%
-
•
vancomycin was released in a pH-controlled manner
-
•
inhibit the activity of S. aureus
|
[285] |
nano-hydroxyapatite scaffolds |
Ag+, nano-hydroxyapatite |
|
[286] |
Black phosphorus nanosheets |
Black phosphorus |
|
[287] |
MoOx-hydroxyapatite nanoparticles |
Hydroxyapatite, MoOx |
|
[288] |